期刊文献+

肾衰康2号抗肾纤维化及其尿毒素清除作用的研究 被引量:2

Prevention of renal fibrosis and clearance of uremia toxin by shenshuaikang 2
下载PDF
导出
摘要 目的观察肾衰康2号对5/6肾切除大鼠所致慢性肾衰肠道清除尿毒素及其延缓肾脏纤维化的作用。方法将5/6肾切除大鼠分为肾衰康治疗组和对照组,并设假手术组为正常对照。普通喂养10周后检测各组的血清及粪便尿素氮、肌酐,并留取肾组织作病理,免疫组化法检测肾组织内纤维连接蛋白(FN)的表达水平。结果肾衰康2号治疗组血清尿素氮、肌酐较对照组下降(P<0.05),粪便尿素氮、肌酐水平较对照组升高(P<0.05),病理切片显示治疗组残余肾小球体积、直径与对照组相比明显减小(P<0.05),肾小球系膜细胞、基质的增生程度亦明显减轻(P<0.05),免疫组化显示,治疗组肾小球内FN的沉积比对照组减少(P<0.05)。结论肾衰康2号有延缓肾纤维化,促进尿毒素排泄的作用。 Objective To observe the clearance of uremia toxin through intestinal tract by shenshuaikang 2 and its effect on the prevention of the renal fibrosis in chronic renal failure rats with 5/6nephronectorny. Methods Subtotally nephrectomized rats were randomly assigned to shenshuaikang 2 lreatrnent group and no, treatment group. Sham-operation rats served as a normal control group. BUN, Cr, stool BUN, and Cr were measured at 10th week following the operation. Renal pathology changes were evaluated at 10th week Irnrnunohistochernistry was used to examine the expression of fibroneetin in glornerulus. Results Shenshuaikang 2 not only increased clearance of BUN and Cr through the intestinal tract, decreased BUN, Cr (P〈0.05), but also ameliorated rnesangial tissue proliferation, reduced fibronectin deposition, and relieved compensatory hypertrophy in remnant renal glomerulus of 5/6 nephrectomized rats (P〈0.05). Conclusion Shenshuaikang 2 can delay the progression of renal fibrosis and increase clearance of uremia toxin.
出处 《中南药学》 CAS 2008年第6期648-651,共4页 Central South Pharmacy
关键词 慢性肾功能衰竭 肠道透析 尿毒素 纤维连接蛋白 肾脏病理 chronic renal failure intestinal dialysis uremic toxin fibronectin renal pathology
  • 相关文献

参考文献10

二级参考文献111

共引文献173

同被引文献18

  • 1李俊霞,蒋云生.肾衰康清除中分子物质的临床研究[J].中国现代医学杂志,2005,15(21):3259-3261. 被引量:6
  • 2Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease [J]. Curr Vasc Pharmacol, 2010, 8 (1) : 122-128.
  • 3Prakash S, Prasad N, Sharma RK. Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease [J]. Cytokine, 2012, 58 ( 2 ) : 261-266.
  • 4Raij L, Azar S, Keane W. Mesangial immune injury, hyper- tension, and progressive glomerular damage in Dahl rats [J]. Kidneylnt, 1984, 26: 137-143.
  • 5Radford MG Jr, Donadio JV, Bergstrlh EJ, et al. Predicting renal outcome in IgA nephropathy [J]. J Am Soc Nephrol, 1997, 8 (2) : 199-207.
  • 6Gao D, Zhao ZZ, Liang XH, et al. Effect of peritoneal dia- lysis on expression of vascular endothelial growth factor, basic fibroblast growth factor and endostatin of the peritoneum in peritoneal dialysis patients [J]. Nephrology, 2011, 16 ( 8 ) : 736-742.
  • 7Liu F, Li Y, Wang F, et al. Shenfushu granu leand atropine attenuate microvasculature loss in rat models with 5/6 nephrectomy renal failure [J]. 2012, 34 ( 5 ) : 600-609.
  • 8Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease [ J ]. Curr Vase Pharmaco1,2010,8 ( 1 ) : 122-128.
  • 9Prakash S, Prasad N, Sharma RK, et al. Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease[J]. Cytokine,2012,58(2) :261-266.
  • 10Liu F, Li Y, Wang F, et al. Shenfushu granule and atropine atten- uate microvasculature loss in rat models with 5/6 nephrectomy [J]. Ren Fail,2012,34(5) :600-609.

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部